Approved by the FDA in July 2023, Lequembi is a monoclonal antibody that does not offer a cure to the disease but has shown promise in slowing cognitive decline in early stage Alzheimer’s patients.
The approval process and regimen include multiple diagnostic tests and insurance has been an significant obstacle, with some coverage denials and delays because of the drugs high cost and novelty.
Biogen and Eisai are working on more accessible forms of the drug, including a maintenance dose and a subcutaneous version to ease the burden on patients and broaden its use.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
